BMS defends Celgene buyout ahead of shareholder vote

BMS battles for hearts and minds before shareholder vote. Bristol-Myers Squibb is looking to convince investors that its $74bn takeover of Celgene is a sound move, ahead of a key

CHMP recommends new Keytruda dosing schedule

A decision is expected from the EMA during the second quarter of 2019, and the decision could put even more pressure on its main rival Opdivo, Bristol-Myers Squibb’s

AZ to address Imfinzi setback, but sees potential with Tagrisso

Bristol-Myers Squibb also followed a similar pattern with its PD-1 inhibitor Opdivo, after it failed in first-line NSCLC, but paired that drug up with its CTLA4 inhibitor Yervoy.

BMS trades blows with investor on Celgene deal merits

Activist investors claim Celgene’s pipeline is “extremely risky”. Bristol-Myers Squibb has issued a defence of its proposed $74bn merger, with Celgene as an activist fund steps up its attempts

1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]